# US 2023/0069722 A1 · Tubulysins and protein-tubulysin conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069722 A1
- Document ID: US20230069722A1
- Status: Published application
- Kind: A1
- Application number: 17/356,497
- Filed: 2021-06-23
- Published: 2023-03-02
- Earliest claimed: 2020-06-24
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Amy HAN
- Web page: https://patentgrep.com/patent/US20230069722A1

## CPC

- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07K 5/021: {containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds}
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.

## Claims

### Claim 1

A compound having the following formula
or a pharmaceutically acceptable salt thereof, wherein
BA is a binding agent;
L is a linker covalently bound to BA and to T;
T is
wherein
R1 is a bond, hydrogen, C1-C10 alkyl, a first N-terminal amino acid residue, a first amino acid residue, —C1-C10 alkyl-NR3aR3b, or —C1-C10 alkyl-OH;
R3 is hydroxyl, —O—, —O—C1-C5 alkyl, —OC(O)C1-C5 alkyl, —OC(O)N(H)C1-C10 alkyl, —OC(O)N(H)C1-C10 alkyl-NR3aR3b, —NHC(O)C1-C5 alkyl, or —OC(O)N(H)(CH2CH2O)nC1-C10 alkyl-NR3aR3b,
wherein R3a and R3b are independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R4 and R5 are, independently in each instance, hydrogen or C1-C5 alkyl;
R6 is —OH, —O—, —NHNH2, —NHNH—, —NHSO2(CH2)a1-aryl-(CH2)a2NR6aR6b,
wherein aryl is substituted or unsubstituted; and
R6a and R6b are independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R7 is, independently in each instance, hydrogen, —OH, —O—, halogen, or —NR7aR7b,
wherein R7a and R7b are, independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, —C(O)CH2OH, —C(O)CH2O—, a first N-terminal amino acid residue, a first amino acid residue, a first N-terminal peptide residue, a first peptide residue, —CH2CH2NH2, and —CH2CH2NH—; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R8 is, independently in each instance, hydrogen, —NHR9, or halogen,
wherein R9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and
m is one or two;
R10, when present, is —C1-C5 alkyl;
Q is —CH2— or —O— wherein
R2 is alkyl, alkylene, alkynyl, alkynylene, a regioisomeric triazole, a regioisomeric triazolylene;
wherein said regioisomeric triazole or regioisomeric triazolylene is unsubstituted or substituted with alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or acyl;
wherein n is an integer from one to ten;
wherein r is an integer from one to six;
wherein a, a1, and, a2 are, independently, zero or one; and
k is an integer from one to thirty;
wherein T is not compound IVa, IVa′, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVj, IVk, IVl, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu, IVvA, IVvB, IVw, IVx, IVy, Va, Va′, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, VIa, IVb, VIc, VId, VIe, VIf, VIg, VIh, Vi, VIi, VII, VIII, IX, X, D-5a, and D-5c, or a pharmaceutically acceptable salt thereof, covalently bound to L.

### Claim 2 (depends on 1)

The compound of claim 1, having a Formula A, B, C, D, or E
wherein L is a linker.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof,
wherein
R7 is, independently in each instance, hydrogen, —OH, —O—, halogen, or —NR7aR7b,
wherein R7a and R7b are, independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, —C(O)CH2OH, —C(O)CH2O—, a first N-terminal amino acid residue, a first N-terminal peptide residue, —CH2CH2NH2, and —CH2CH2NH—, wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted.

### Claim 4 (depends on 2)

The compound of claim 2, wherein the compound is of the Formula A′, B′, C′, D′, or E′
wherein SP1 and SP2, when present, are spacer groups;
each AA, when present, is a second amino acid residue; and
p is an integer from zero to ten.

### Claim 5 (depends on 4)

The compound of claim 4, wherein
the -SP2- spacer, when present, is
the second -(AA)p- is
the -SP1- spacer is
wherein RG′ is a reactive group residue following reaction of a reactive group RG with a binding agent;
is a bond, direct or indirect, to the binding agent; and
b is an integer from one to four.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the binding agent is an antibody modified with a primary amine compound according to the Formula H2N-LL-X, wherein LL is a divalent linker selected from the group consisting of
a divalent polyethylene glycol (PEG) group;
—(CH2)n—;
—(CH2CH2O)n—(CH2)p—;
—(CH2)n—N(H)C(O)—(CH2)m—;
—(CH2CH2O)n—N(H)C(O)—(CH2CH2O)m—(CH2)p—;
—(CH2)n—C(O)N(H)—(CH2)m—;
—(CH2CH2O)n—C(O)N(H)—(CH2CH2O)m—(CH2)p—;
—(CH2)n—N(H)C(O)—(CH2CH2O)m—(CH2)p—;
—(CH2CH2O)n—N(H)C(O)—(CH2)m—;
—(CH2)n—C(O)N(H)—(CH2CH2O)m—(CH2)p—; and
—(CH2CH2O)n—C(O)N(H)—(CH2)m—,
wherein
n is an integer selected from one to twelve;
m is an integer selected from zero to twelve;
p is an integer selected from zero to two; and
X is selected from the group consisting of —SH, —N3, —C≡CH, —C(O)H, tetrazole,

### Claim 7 (depends on 6)

The compound of claim 6, wherein the binding agent is an antibody modified with a primary amine according to the following formula

### Claim 8 (depends on 4)

The compound of claim 4, wherein Q is —O—.

### Claim 9 (depends on 4)

The compound of claim 4, wherein
Q is —CH2—;
R1 is C1-C10 alkyl;
R2 is alkyl;
R4 and R5 are C1-C5 alkyl;
R6 is —OH;
R10 is absent;
wherein r is four; and
wherein a is one.

### Claim 10 (depends on 9)

The compound of claim 9, according to the structure of C′, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R7 is —NH—; and R8 is hydrogen or fluoro.

### Claim 12 (depends on 9)

The compound of claim 9, according to the structure of E′, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R3 is —OC(O)N(H)CH2CH2NH—or —OC(O)N(H)CH2CH2OCH2CH2OCH2CH2OCH2CH2NH—.

### Claim 14 (depends on 4)

The compound of claim 4, wherein
Q is —CH2—;
R1 is hydrogen or C1-C10 alkyl;
R2 is alkyl;
R4 and R5 are C1-C5 alkyl;
R6 is —OH;
wherein r is three or four; and
wherein a is one.

### Claim 15 (depends on 14)

The compound of claim 14, according to the structure of C′, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R7 is —NH—; and R8 is hydrogen.

### Claim 17 (depends on 4)

The compound of claim 4, wherein
Q is —CH2—;
R1 is hydrogen or C1-C10 alkyl;
R2 is alkyl;
R4 and R5 are C1-C5 alkyl;
R6 is —OH;
R10 is absent;
wherein r is four; and
wherein a is one.

### Claim 18 (depends on 17)

The compound of claim 17, according to the structure of C′, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R7 is —NH—; and R8 is hydrogen.

### Claim 20 (depends on 4)

The compound of claim 4, wherein
Q is —O—;
R1 is hydrogen or C1-C10 alkyl;
R2 is alkyl or alkynyl;
R3 is hydroxyl or —OC(O)C1-C5 alkyl;
R4 and R5 are C1-C5 alkyl;
R6 is —OH;
R10, when present, is —C1-C5 alkyl;
wherein r is three or four; and
wherein a is one.

### Claim 21 (depends on 20)

The compound of claim 20, according to the structure of C′, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R7 is —NH—; and R8 is hydrogen.

### Claim 23 (depends on 4)

The compound of claim 4, wherein
Q is —CH2— or —O—;
R1 is C1-C10 alkyl;
R2 is alkyl or alkynyl;
R4 and R5 are C1-C5 alkyl;
R6 is —NHSO2(CH2)a1-aryl-(CH2)a2NR6aR6b;
R10 is absent;
wherein r is four; and
wherein a, a1, and, a2 are, independently, zero or one.

### Claim 24 (depends on 23)

The compound of claim 23, according to the structure of B′, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R6 is

### Claim 26 (depends on 24)

The compound of claim 24, wherein a is zero; and R6 is

### Claim 27 (depends on 24)

The compound of claim 24, wherein a is one; and R6 is

### Claim 28 (depends on 21)

The compound of claim 21, wherein R7 is —O—; and R8 is hydrogen.

### Claim 29 (depends on 4)

The compound of claim 4, selected from the group consisting of
or a pharmaceutically acceptable salt thereof,
wherein BA is a binding agent; and k is one, two, three, or four.

### Claim 30 (depends on 29)

The compound of claim 29, wherein BA is an antibody or antigen-binding fragment thereof.

### Claim 31 (depends on 29)

The compound of claim 29, wherein BA is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least one glutamine residue used for conjugation.

### Claim 32 (depends on 29)

The compound of claim 29, wherein BA is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least two glutamine residues used for conjugation.

### Claim 33 (depends on 29)

The compound of claim 29, wherein BA is a transglutaminase-modified antibody or antigen-binding fragment thereof comprising at least four glutamine residues used for conjugation.

### Claim 34 (depends on 33)

The compound of claim 33, wherein BA is a transglutaminase-modified antibody or antigen-binding fragment thereof wherein conjugation is at two Q295 residues; and k is two.

### Claim 35 (depends on 33)

The compound of claim 33, wherein BA is a transglutaminase-modified antibody or antigen-binding fragment thereof wherein conjugation is at two Q295 residues and two N297Q residues; and k is four.

### Claim 36 (depends on 1)

The compound of claim 1, wherein the compound is an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof conjugated to a compound selected from the group consisting of

### Claim 37 (depends on 29)

The compound of claim 29, wherein BA or the antibody or antigen-binding fragment thereof is selected from the group consisting of anti-MUC16, anti-PSMA, anti-EGFRvIII, anti-HER2, and anti-MET.

### Claim 38 (depends on 29)

The compound of claim 29, wherein BA or the antibody or antigen-binding fragment thereof is anti-PRLR or anti-STEAP2.

### Claim 39 (depends on 29)

The compound of claim 29, wherein BA or the antibody or antigen-binding fragment thereof binds to an antigen selected from the group consisting of lipoproteins; alpha1-antitrypsin; a cytotoxic T-lymphocyte associated antigen (CTLA), such as CTLA-4 or CTLA4; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; protein A or D; fibroblast growth factor receptor 2 (FGFR2), EpCAM or Epcam, GD3, FLT3, PSCA, MUC1 or Muc1, MUC16 or Muc16, STEAP, STEAP2 or Steap-2, CEA, TENB2, EphA receptors, EphB receptors, folate receptor, FOLRI, mesothelin, cripto, alphavbeta6, VEGFR, EGFR, transferrin receptor, IRTA1, IRTA2, IRTA3, IRTA4, IRTA5; CD proteins such as CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD19, CD20, CD21, CD22, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD59, CD70, CD79, CD80, CD81, CD103, CD105, CD134, CD137, CD138, CD152; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); T-cell receptors; surface membrane proteins; integrins, such as CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as AFP, ALK, B7H4, BAGE proteins, 0-catenin, brc-abl, BRCA1, BORIS, CA9 (carbonic anhydrase IX), caspase-8, CD123, CDK4, CLEC12 Å, c-kit, cMET, c-MET, MET, cyclin-B1, CYP1B1, EGFRvIII, endoglin, EphA2, ErbB2/Her2, ErbB3/Her3, ErbB4/Her4, ETV6-AML, Fra-1, FOLR1, GAGE proteins such as GAGE-1 and GAGE-2, GD2, GloboH, glypican-3, GM3, gp100, Her2 or HER2, HLA/B-raf, HLA/EBNA1, HLA/k-ras, HLA/MAGE-A3, hTERT, IGF1R, LGR5, LMP2, MAGE proteins such as MAGE-1, -2, -3, -4, -6, and -12, MART-1, ML-IAP, CA-125, MUM1, NA17, NGEP, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PDGFR-a, PDGFR-0, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PLAC1, PRLR, PRAME, PSGR, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, STn, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TNFRSF17, TRP-1, TRP-2, tyrosinase, uroplakin-3, fragments of any of the above-listed polypeptides; cell-surface expressed antigens; molecules such as class A scavenger receptors including scavenger receptor A (SR-A), and other membrane proteins such as B7 family-related member including V-set and Ig domain-containing 4 (VSIG4), Colony stimulating factor 1 receptor (CSF1R), asialoglycoprotein receptor (ASGPR), and Amyloid beta precursor-like protein 2 (APLP-2); BCMA; SLAMF7; GPNMB; and UPK3 Å.

### Claim 40

A compound having the structure of Formula I
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, C1-C10 alkyl, a first N-terminal amino acid residue, —C1-C10 alkyl-NR3aR3b, or —C1-C10 alkyl-OH;
R3 is hydroxyl, —O—C1-C5 alkyl, —OC(O)C1-C5 alkyl, —OC(O)N(H)C1-C10 alkyl, —OC(O)N(H)C1-C10 alkyl-NR3aR3b, —NHC(O)C1-C5 alkyl, or —OC(O)N(H)(CH2CH2O)nC1-C10 alkyl-NR3aR3b,
wherein R3a and R3b are independently in each instance, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R4 and R5 are, independently in each instance, hydrogen or C1-C5 alkyl;
R6 is —OH, —NHNH2, —NHSO2(CH2)a1-aryl-(CH2)a2NR6aR6b,
wherein aryl is substituted or unsubstituted; and
R6a and R6b are independently in each instance, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R7 is, independently in each instance, hydrogen, —OH, halogen, or —NR7aR7b,
wherein R7a and R7b are, independently in each instance, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, —C(O)CH2OH, a first N-terminal amino acid residue, a first N-terminal peptide residue, and —CH2CH2NH2; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R8 is, independently in each instance, hydrogen, —NHR9, or halogen,
wherein R9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and
m is one or two;
R10, when present, is —C1-C5 alkyl;
Q is —CH2— or —O— wherein
R2 is alkyl, alkynyl, or a regioisomeric triazole;
wherein said regioisomeric triazole is unsubstituted or substituted with alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl;
wherein n is an integer from one to ten;
wherein r is an integer from one to six;
wherein a, a1, and, a2 are, independently, zero or one; and
wherein T is not compound IVa, IVa′, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVj, IVk, IVl, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu, IVvA, IVvB, IVw, IVx, IVy, Va, Va′, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, VIa, IVb, VIc, VId, VIe, VIf, VIg, VIh, VI, VIi, VII, VIII, IX, X, D-5a, D-5c, Tubulysin A-I, U-X, or Z, Pretubulysin D, or N14-desacetoxytubulysin H.

### Claim at position 41

-67. (canceled)

### Claim 68 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 69 (depends on 1)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the compound of claim 1.

### Claim 70 (depends on 40)

A method for treating cancer in a subject comprising administering to the subject an effective treatment amount of the compound of claim 40.

### Claim 71 (depends on 1)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the compound of claim 1, wherein the cancer is selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, head and neck cancer, prostate cancer, castrate-resistant prostrate cancer, malignant gliomas, osteosarcoma, colorectal cancer, gastric cancer, mesothelioma, malignant mesothelioma, multiple myeloma, ovarian cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer, PRLR positive (PRLR+) breast cancer, melanoma, acute myelogenous leukemia, adult T-cell leukemia, astrocytomas, bladder cancer, cervical cancer, cholangiocarcinoma, endometrial cancer, esophageal cancer, glioblastomata, Kaposi's sarcoma, kidney cancer, leiomyosarcomas, liver cancer, lymphomas, MFH/fibrosarcoma, nasopharyngeal cancer, rhabdomyosarcoma, colon cancer, stomach cancer, uterine cancer, residual cancer, and Wilms' tumor.

### Claim 72 (depends on 40)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the compound of claim 40, wherein the cancer is selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, head and neck cancer, prostate cancer, castrate-resistant prostrate cancer, malignant gliomas, osteosarcoma, colorectal cancer, gastric cancer, mesothelioma, malignant mesothelioma, multiple myeloma, ovarian cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer, PRLR positive (PRLR+) breast cancer, melanoma, acute myelogenous leukemia, adult T-cell leukemia, astrocytomas, bladder cancer, cervical cancer, cholangiocarcinoma, endometrial cancer, esophageal cancer, glioblastomata, Kaposi's sarcoma, kidney cancer, leiomyosarcomas, liver cancer, lymphomas, MFH/fibrosarcoma, nasopharyngeal cancer, rhabdomyosarcoma, colon cancer, stomach cancer, uterine cancer, residual cancer, and Wilms' tumor.

### Claim 73

A method for treating tumors that express an antigen selected from the group consisting of PRLR and STEAP2.

### Claim 74

A linker-payload having the formula
L-T
or a pharmaceutically acceptable salt thereof, wherein
L is a linker covalently bound to T;
T is
wherein
R1 is a bond, hydrogen, C1-C10 alkyl, a first N-terminal amino acid residue, a first amino acid residue, —C1-C10 alkyl-NR3aR3b, or —C1-C10 alkyl-OH;
R3 is hydroxyl, —O—, —O—C1-C5 alkyl, —OC(O)C1-C5 alkyl, —OC(O)N(H)C1-C10 alkyl, —OC(O)N(H)C1-C10 alkyl-NR3aR3b, —NHC(O)C1-C5 alkyl, or —OC(O)N(H)(CH2CH2O)nC1-C10 alkyl-NR3aR3b,
wherein R3a and R3b are independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R4 and R5 are, independently in each instance, hydrogen or C1-C5 alkyl;
R6 is —OH, —O—, —NHNH2, —NHNH—, —NHSO2(CH2)a1-aryl-(CH2)a2NR6aR6b,
wherein aryl is substituted or unsubstituted; and
R6a and R6b are independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R7 is, independently in each instance, hydrogen, —OH, —O—, halogen, or —NR7aR7b,
wherein R7a and R7b are, independently in each instance, a bond, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, —C(O)CH2OH, —C(O)CH2O—, a first N-terminal amino acid residue, a first amino acid residue, a first N-terminal peptide residue, a first peptide residue, —CH2CH2NH2, and —CH2CH2NH—; wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted;
R8 is, independently in each instance, hydrogen, —NHR9, or halogen,
wherein R9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and
m is one or two;
R10, when present, is —C1-C5 alkyl;
Q is —CH2— or —O— wherein
R2 is alkyl, alkylene, alkynyl, alkynylene, a regioisomeric triazole, a regioisomeric triazolylene;
wherein said regioisomeric triazole or regioisomeric triazolylene is unsubstituted or substituted with alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or acyl;
wherein n is an integer from one to ten;
wherein r is an integer from one to six;
wherein a, a1, and, a2 are, independently, zero or one; and
wherein the linker-payload is not LP1-IVa, LP2-Va, LP3-IVd, LP4-Ve, LP5-IVd, LP6-Vb, LP7-IVd, LP9-IVvB, LP10-VIh, LP11-IVvB, LP12-VIi, LP13-Ve, LP14-Ve, LP15-VIh, LP16-Ve, LP17-Ve, LP18-Ve, LP19-Ve, LP20-Ve, LP21-Ve, LP22-Ve, LP23-Vb, LP24-Vb, LP25-Ve, and LP26-Ve, or a pharmaceutically acceptable salt thereof.

### Claim at position 49

-100. (canceled)

### Claim 101 (depends on 40)

A pharmaceutical composition comprising the compound of claim 40 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 102 (depends on 68)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the pharmaceutical composition of claim 68.

### Claim 103 (depends on 101)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the pharmaceutical composition of claim 101.

### Claim 104 (depends on 68)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the pharmaceutical composition of claim 68, wherein the cancer is selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, head and neck cancer, prostate cancer, castrate-resistant prostrate cancer, malignant gliomas, osteosarcoma, colorectal cancer, gastric cancer, mesothelioma, malignant mesothelioma, multiple myeloma, ovarian cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer, PRLR positive (PRLR+) breast cancer, melanoma, acute myelogenous leukemia, adult T-cell leukemia, astrocytomas, bladder cancer, cervical cancer, cholangiocarcinoma, endometrial cancer, esophageal cancer, glioblastomata, Kaposi's sarcoma, kidney cancer, leiomyosarcomas, liver cancer, lymphomas, MFH/fibrosarcoma, nasopharyngeal cancer, rhabdomyosarcoma, colon cancer, stomach cancer, uterine cancer, residual cancer, and Wilms' tumor.

### Claim 105 (depends on 101)

A method for treating cancer in a subject comprising administering to the subject of an effective treatment amount of the pharmaceutical composition of claim 101, wherein the cancer is selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, head and neck cancer, prostate cancer, castrate-resistant prostrate cancer, malignant gliomas, osteosarcoma, colorectal cancer, gastric cancer, mesothelioma, malignant mesothelioma, multiple myeloma, ovarian cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer, PRLR positive (PRLR+) breast cancer, melanoma, acute myelogenous leukemia, adult T-cell leukemia, astrocytomas, bladder cancer, cervical cancer, cholangiocarcinoma, endometrial cancer, esophageal cancer, glioblastomata, Kaposi's sarcoma, kidney cancer, leiomyosarcomas, liver cancer, lymphomas, MFH/fibrosarcoma, nasopharyngeal cancer, rhabdomyosarcoma, colon cancer, stomach cancer, uterine cancer, residual cancer, and Wilms' tumor.
